Analyst Ratings For BioMarin Pharmaceutical (NASDAQ:BMRN)
Today, Sanford C. Bernstein initiated coverage on BioMarin Pharmaceutical (NASDAQ:BMRN) with a Market Perform with a price target of $89.00.
There are 7 hold ratings, 14 buy ratings on the stock.
The current consensus rating on BioMarin Pharmaceutical (NASDAQ:BMRN) is Buy (Score: 2.67) with a consensus target price of $112.05 per share, a potential 25.62% upside.
Some recent analyst ratings include
- 7/27/2017-Sanford C. Bernstein initiated coverage with a Market Perform rating.
- 7/22/2017-Barclays PLC Reiterated Rating of Equal Weight.
- 7/18/2017-Leerink Swann Reiterated Rating of Buy.
- 7/14/2017-SunTrust Banks, Inc. Reiterated Rating of Buy.
- 7/13/2017-BMO Capital Markets Reiterated Rating of Outperform.
- 7/11/2017-Cowen and Company Reiterated Rating of Buy.
- 5/15/2017-Jefferies Group LLC Reiterated Rating of Buy.
Recent Insider Trading Activity For BioMarin Pharmaceutical (NASDAQ:BMRN)
BioMarin Pharmaceutical (NASDAQ:BMRN) has insider ownership of 2.50% and institutional ownership of 96.63%.
- On 6/23/2017 George Eric Davis, EVP, sold 9,844 with an average share price of $96.60 per share and the total transaction amounting to $950,930.40. View SEC Filing
- On 6/22/2017 Brian Mueller, SVP, sold 2,671 with an average share price of $100.00 per share and the total transaction amounting to $267,100.00. View SEC Filing
- On 6/19/2017 Henry J Fuchs, Insider, sold 15,000 with an average share price of $90.00 per share and the total transaction amounting to $1,350,000.00. View SEC Filing
- On 6/16/2017 V Bryan Lawlis, Director, sold 3,750 with an average share price of $90.00 per share and the total transaction amounting to $337,500.00. View SEC Filing
- On 6/7/2017 Jeffrey Robert Ajer, EVP, sold 1,004 with an average share price of $89.61 per share and the total transaction amounting to $89,968.44. View SEC Filing
- On 6/5/2017 George Eric Davis, EVP, sold 9,471 with an average share price of $91.04 per share and the total transaction amounting to $862,239.84. View SEC Filing
- On 6/5/2017 Jean Jacques Bienaime, CEO, sold 10,000 with an average share price of $90.13 per share and the total transaction amounting to $901,300.00. View SEC Filing
Recent Trading Activity for BioMarin Pharmaceutical (NASDAQ:BMRN)
Shares of BioMarin Pharmaceutical closed the previous trading session at 89.20 0.00 0.00% with 1,031,607 shares trading hands.